exRNAdisease

Entry Detail

---



General Information

Database ID: exR0274372 RNA Name: hsa-miR-103a-3p RNA Type: miRNA Chromosome: chr5 Starnd: - Coordinate: Start Site(bp): 168560904 End Site(bp): 168560926 External Links: hsa-miR-103a-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE22981 Description: Circulating miRNAs as biomarkers and potential functional mediators of early stage breast cancer Experimental Design: Cancer vs Control Case Disease Type: Breast Cancer Case Disease SubType: Early satge breast cancer Case Sample: Breast Cancer Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand RCCD1 chr15 90954870 90963125 + CA12 chr15 63321378 63381846 - AMER1 chrX 64185117 64205708 - PLPP6 chr9 4662294 4665258 + ERG28 chr14 75649791 75660876 - SCAMP4 chr19 1905372 1926013 + DPP3 chr11 66480013 66509657 + AC011455.2 chr19 38915404 38949855 - UBN1 chr16 4846665 4882401 + TMX2 chr11 57712593 57740973 + RNF157 chr17 76142465 76240493 - NAA60 chr16 3443649 3486953 + MRPS2 chr9 135499984 135504673 + TSPYL2 chrX 53082367 53088540 + KLHL21 chr1 6590724 6614607 - TUBA1B chr12 49127782 49131397 - STEAP3 chr2 119223831 119265652 + MRPL3 chr3 131462212 131502983 - STK16 chr2 219245455 219250337 + ABCF2 chr7 151207837 151227166 - RPS6KA3 chrX 20149911 20267519 - DCAF7 chr17 63550477 63594279 + CNN2 chr19 1026586 1039068 + SRPK1 chr6 35832966 35921342 - ZNF697 chr1 119619377 119648266 - LYSMD2 chr15 51723011 51751585 - PODXL chr7 131500262 131558217 - EBP chrX 48521799 48528716 + RPS14 chr5 150442635 150449739 - PKM chr15 72199029 72231822 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000712 chr16 68208276 68225678 + hsa_circ_0001723 chr7 91924202 91948826 + hsa_circ_0001495 chr5 68470703 68471364 + hsa_circ_0001168 chr20 47691321 47707559 + hsa_circ_0000652 chr15 90984737 90986710 + hsa_circ_0001472 chr5 36953719 36976504 + hsa_circ_0001164 chr20 45891031 45923523 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC003092.1 chr7 94022833 94066661 + AC018521.1 chr17 47945424 47981736 + AC021078.1 chr5 149494314 149504670 - AC021092.1 chr19 44103007 44113183 - AC093297.2 chr5 44826076 44828592 + AL137127.1 chr1 19072110 19075511 - FGD5-AS1 chr3 14920347 14948424 - H19 chr11 1995176 2001470 - LINC00294 chr11 33076149 33079454 + LINC00662 chr19 27681072 27794005 - LINC02035 chr3 122886941 122892416 + MIR503HG chrX 134543119 134546642 - NEAT1 chr11 65422774 65445540 + NUTM2A-AS1 chr10 87201647 87342612 - NUTM2B-AS1 chr10 79661394 79826594 - STAG3L5P-PVRIG2P-PILRB chr7 100336104 100367831 + TMEM147-AS1 chr19 35540738 35546029 - TTC28-AS1 chr22 27919376 28008581 + TTN-AS1 chr2 178521183 178779963 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE22981 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 801 Sample treatment protocol: NA RNA Extract protocol: Total RNA, including miRNA from plasma, was isolated using the miRNeasy kit (Qiagen) with minor modifications. RNA library preparation protocol: Two hundred ng of total RNA from each sample were labeled and hybridized on Human v2 MicroRNA Expression BeadChips (Cat. no. MI-102-1024; Illumina).

Reference

PMID: 21060830 Title: A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer Author: Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu SBACKGROUND: To date, there are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer at an early stage. The occurrence of circulating microRNAs (miRNAs) in blood components (including serum and plasma) has been repeatedly observed in cancer patients as well as healthy controls. Because of the significance of miRNA in carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers. METHODOLOGY/PRINCIPAL FINDINGS: Using microarray-based expression profiling followed by Real-Time quantitative Polymerase Cycle Reaction (RT-qPCR) validation, we compared the levels of circulating miRNAs in plasma samples from 20 women with early stage breast cancer (10 Caucasian American (CA) and 10 African American (AA)) and 20 matched healthy controls (10 CAs and 10 AAs). Using the significance level of p<0.05 constrained by at least two-fold expression change as selection criteria, we found that 31 miRNAs were differentially expressed in CA study subjects (17 up and 14 down) and 18 miRNAs were differentially expressed in AA study subjects (9 up and 9 down). Interestingly, only 2 differentially expressed miRNAs overlapped between CA and AA study subjects. Using receiver operational curve (ROC) analysis, we show that not only up-regulated but also down-regulated miRNAs can discriminate patients with breast cancer from healthy controls with reasonable sensitivity and specificity. To further explore the potential roles of these circulating miRNAs in breast carcinogenesis, we applied pathway-based bioinformatics exploratory analysis and predicted a number of significantly enriched pathways which are predicted to be regulated by these circulating miRNAs, most of which are involved in critical cell functions, cancer development and progression. CONCLUSIONS: Our observations from this pilot study suggest that the altered levels of circulating miRNAs might have great potential to serve as novel, noninvasive biomarkers for early detection of breast cancer. Journal: PLoS One. 2010 Oct 29;5(10):e13735. Description: The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers.